相关临床试验
1
1 进行中
药物批准
0
批准总数
监管机构
0
监管机构数
成立时间
N/A
暂无试验阶段数据
尚未招募
1
100.0%
暂无批准数据
- PrecisionLife and Ovation identified genetic biomarkers that can quantitatively predict patient response to GLP-1 receptor agonist therapies using data from 4,600 patients. - The collaboration generated over 2,500 genetic signatures mapped to 1,100 genes with 15 main genetic mechanisms driving GLP-1 efficacy, with biomarkers identified in 100% of patients. - The companies are expanding their partnership to include 25,000 patients to validate findings and identify safety and tolerability markers, addressing the 50% discontinuation rate within 12 months. - The biomarkers could enable precision prescribing and inform reimbursement decisions for GLP-1 therapies, which represent over $70 billion in annual US spending.
- PrecisionLife and Ovation.io announced a collaboration to develop drug-response biomarkers for GLP-1 receptor agonist therapies using multiomic data from 25,000 US patients. - The partnership aims to create a payor-facing test to inform reimbursement policy based on patient potential to tolerate and respond to GLP-1 drugs in specific indications. - GLP-1s represent one of the fastest-growing therapeutic classes globally, driving a $95 billion obesity market by 2030, with 30-70 million prescriptions expected annually in the US. - The initiative will develop a Mechanostic® test to help payors determine where GLP-1 therapies are most clinically and economically justified through value-based reimbursement frameworks.
- Illumina and Ovation.io are developing the largest commercial multiomic dataset from 25,000 patients treated with GLP-1 receptor agonists, integrating clinical, genomic, and proteomic data to advance drug development. - The initiative addresses a critical need, as approximately 40% of Type 2 diabetes patients do not respond effectively to GLP-1 therapies, despite one in eight U.S. adults having used these medications. - The dataset will leverage Illumina's next-generation sequencing technologies to sequence whole genomes and profile protein expression, potentially unlocking new indications and identifying novel biomarkers for non-responsive patients.
